No Data
There Are Reasons To Feel Uneasy About Innovita Biological Technology's (SHSE:688253) Returns On Capital
Third Quarter Report 2024
Innotek (688253.SH): The net income for the first three quarters was 0.24 billion yuan, a year-on-year increase of 182.65%.
Gelonghui October 25th | Innotek (688253.SH) released its third-quarter report, with a third-quarter revenue of 0.52 billion yuan, an 87.05% year-on-year increase, a net income of 0.24 billion yuan, a 182.65% year-on-year increase, a non-net income of 0.22 billion yuan, a 239.12% year-on-year increase, and basic earnings per share of 1.80 yuan.
Innotek (688253.SH) subsidiary recently obtained 4 product qualifications
Innotek (688253.SH) announced that its wholly-owned subsidiary Innotek (Tangshan) Biotechnology Co., Ltd...
Insiders Were the Key Beneficiaries as Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Market Cap Rises to CN¥5.4b
Innotek (688253.SH): First repurchase of 0.0259 million shares of the company's stock.
On September 6, 2024, Innotek (688253.SH) announced that the company repurchased 25,919 shares of the company for the first time through the trading system of the Shanghai Stock Exchange by centralized competitive trading, accounting for 0.0190% of the total share capital of 136,060,816 shares. The highest price for the repurchase transaction was 36.00 yuan/share, and the lowest price was 35.93 yuan/share. The total amount paid was 933,013.45 yuan (excluding stamp duty, trading commission, and other trading expenses).
Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?No Data
No Data
